CLL therapy has changed dramatically over the last few years. This development has been aided by progress in 2 areas: (1) a better understanding of CLL biology (and with it discovery and characterization of new prognostic markers); and (2) emergence of novel agents. The combined impact of advances in these areas is leading to new concepts and approaches in CLL therapy. Treatment of CLL has been...

Introduction of targeted agents revolutionized the treatment of chronic lymphocytic leukemia (CLL) in the past decade. Addition of chimeric monoclonal anti-CD20 antibody rituximab to chemotherapy significantly improved efficacy including overall survival (OS) in untreated fit patients; humanized anti-CD52 antibody alemtuzumab and fully human anti-CD20 antibody ofatumumab lead to improvement in ...